DBV Technologies Highlights Positive Phase 3 Peanut Patch Data

DBV Technologies SA – American ( (DBVT) ) has provided an update.

On February 28, 2026, DBV Technologies reported additional positive Phase 3 data for its VIASKIN Peanut Patch from the VITESSE trial, presented at the AAAAI 2026 Annual Meeting in Philadelphia. The study, the largest food allergy immunotherapy trial to date in peanut‑allergic children aged 4 to 7, met its primary endpoint with 46.6% of treated children classified as responders at 12 months versus 14.8% on placebo, and showed statistically robust results across multiple sensitivity analyses.

New analyses showed about 83% of children on VIASKIN Peanut increased their eliciting dose by at least one step at month 12 compared with roughly 48% on placebo, while around 60% increased by at least two dose levels versus 23% on placebo. Only 6.4% of treated subjects became more sensitized over 12 months compared with 24% on placebo, the patch was generally well tolerated with mostly mild local skin reactions, and company executives said these data underpin plans to seek U.S. regulatory approval, potentially strengthening DBV’s position in the emerging food allergy immunotherapy market if the product is approved.

The most recent analyst rating on (DBVT) stock is a Buy with a $51.00 price target. To see the full list of analyst forecasts on DBV Technologies SA – American stock, see the DBVT Stock Forecast page.

Spark’s Take on DBVT Stock

According to Spark, TipRanks’ AI Analyst, DBVT is a Neutral.

The score is held back primarily by very weak financial performance (minimal/declining revenue, large losses, and heavy ongoing cash burn implying financing risk). Offsetting this are strong clinical/corporate-event momentum from positive Phase 3 results with a planned BLA submission, and supportive technical trends with the stock trading above key moving averages.

To see Spark’s full report on DBVT stock, click here.

More about DBV Technologies SA – American

DBV Technologies S.A. is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. The company is focused on its proprietary VIASKIN patch technology, an epicutaneous immunotherapy designed as a non-invasive approach to desensitize patients—particularly young children—to food allergens such as peanut, and is headquartered in Châtillon, France with North American operations in New Jersey.

Average Trading Volume: 501,767

Technical Sentiment Signal: Buy

Current Market Cap: $1.18B

See more insights into DBVT stock on TipRanks’ Stock Analysis page.